← Human Trials & Peer-Reviewed Studies
Teriparatide Therapy and Reduced Postoperative Hospitalization for Postsurgical Hypoparathyroidism
Plain-language guide to PMID 26312597 (2015): controlled clinical trial study of Teriparatide in 8 patients.
Key Facts
- PMID
- 26312597
- Journal
- JAMA otolaryngology-- head & neck surgery
- Year
- 2015
- Study type
- Controlled Clinical Trial
- Authors
- Shah M et al. (8 authors)
- DOI
- 10.1001/jamaoto.2015.1497
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial paper looks at Teriparatide.
Although usually transient, severe symptomatic hypocalcemia may occur.
Teriparatide acetate (recombinant human parathyroid hormone 1-34) therapy can rapidly raise calcium levels.
Who Took Part
According to the abstract, 8 patients were involved.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Case series of all hospitalized patients 18 years or older treated with teriparatide for symptomatic postthyroidectomy hypocalcemia occurring immediately after thyroidectomy at Mayo Clinic, Rochester, Minnesota, between January 1, 2008, and June 30, 2014.
A secondary analysis was performed with matched control and cohort groups having postthyroidectomy hypocalcemia of similar degree who received standard treatment only.
How the Study Was Run
Participants included 8 hospitalized patients who received teriparatide therapy after 24 hours of standard treatment (cases) and eight control patients selected from a cohort of 1193 thyroidectomies were matched for age, sex, body mass index, and nadir calcium levels.
What Was Measured
Teriparatide acetate (recombinant human parathyroid hormone 1-34) therapy can rapidly raise calcium levels.
Topics PubMed links to this paper include Calcium, Cohort Studies, Hospitalization, Hypocalcemia, Hypoparathyroidism, Postoperative Complications and Teriparatide.
What This Means in Plain Language
This is a controlled clinical trial of Teriparatide in 8 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2015 (JAMA otolaryngology-- head & neck surgery), a journal based in United States.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.